Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
about
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolismEffective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulantsManagement of Venous Thromboembolisms: Part I. The Consensus for Deep Vein ThrombosisConsiderations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant eraManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyComparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-AnalysisThe evolution of anticoagulant therapyAnticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the ArtReview of the cost of venous thromboembolismRisk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-AnalysisClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsWhich patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majorityNew oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similaritiesThe treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitationsPulmonary embolism: new treatments for an old problemChoosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to KnowPharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismDiagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of ThroRecent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulantsDirect oral anticoagulants in the treatment of cancer-associated venous thromboembolism.Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registryEvolving use of new oral anticoagulants for treatment of venous thromboembolismMeasurement of rivaroxaban and apixaban in serum samples of patients.Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients.Risk-adapted management of acute pulmonary embolism: recent evidence, new guidelines.Treatment options for venous thromboembolism: lessons learnt from clinical trials.Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapyOral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE programRivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.Anticoagulant therapy with rivaroxaban in a young patient with paroxysmal nocturnal hemoglobinuria.Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useIs it safe to withhold long-term anticoagulation therapy in patients with small pulmonary emboli diagnosed by SPECT scintigraphy?Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trialPrevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study.Novel Oral Anticoagulants for Venous Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and Reversal AgentsUse of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned AnalysisComparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major BleedingShorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
P2860
Q24187205-DC74557C-9D6D-41D8-B2E0-2290E692B3BEQ26746213-965F1B57-E673-487C-BA42-F200D48DDFF3Q26749273-8E09EB37-C04A-47CB-9EA8-46641C1777D3Q26765299-772AE6FD-4199-4494-AA97-6540EAF87E12Q26766303-E7E802DF-288A-40DB-8A25-E1C70576FF81Q26771581-086EBA72-E97C-45F7-8EC2-B9E0604FF34CQ26771859-9D46A480-DBF1-467A-9618-BBEC4DFBA083Q26776112-CD437A59-CD4E-4CD1-8630-0C7811364D80Q26781947-9AD678D5-A51C-44CE-87D3-18EF606CA5EFQ26783473-F699607F-A7A8-4BB9-839B-D70DD814BC83Q26828817-3E69798A-B45E-4BCA-B3E6-A9577454F4CAQ26849407-00BFB2C8-C87E-4F31-8C6E-76E4859CF0ACQ27001528-84238FF8-8C93-49B8-B769-8A37160CBB82Q27694601-C13FF350-3D28-43A4-BFBA-FEE7E9BB8C6AQ28070346-6AC49EC1-D518-4C84-9D2D-356D6A0A009AQ28074445-B8D16127-F96A-447C-AF28-A5D1A3374E4BQ28087447-D65AFAEF-A72B-400E-9C91-4E5A2A7A47A0Q30315531-2E2DD38E-61EC-47AD-AD72-178CD98922C7Q33851708-CCB35898-05C2-4B6E-8CBE-A8CC30941967Q33875888-0B1CA90D-AF4F-40E1-989B-9CB6EBC5FBD7Q34019616-28F3B52D-B524-404F-B544-AD1741F65D0FQ34047821-402851F9-2CA9-4CB1-BD1A-B983BE7888EFQ34086522-009F240B-DAE9-48D8-89D9-247906707551Q34351204-CA2365C0-7E36-4DDA-BE15-D69B2F712A13Q34463470-4BDEC71C-2789-4510-BF11-3460C20EEC39Q34694544-90F7C01B-4354-4D9C-BD46-339F964A2A12Q35101273-941D0EB6-5B29-448B-AFB3-FCD9EC213F86Q35117399-C35F91ED-21B8-4FE3-9B68-931F738CAD76Q35154171-3BF5D5F6-CC1A-4080-A2D4-9727EF96CFACQ35730774-C2772844-B808-40DE-AFCC-9277BE765420Q36188331-E111B8D8-62CB-43A0-884C-F99D43D6600DQ36800361-5AE89D1B-C8E7-4046-89CC-91EF43A0FB3DQ36950048-B7AFDB0D-96D7-4C55-B2F0-52B0987E2BA4Q37007416-C96171FE-41C8-4999-9E0E-0AE886546032Q37027535-F385AA6B-18E9-4E46-9D59-3FD3B971416DQ37213211-44C92B29-BEA9-4B72-BB3F-957B9BB532A0Q37257471-EFCCF357-1337-46BD-A7F3-50ABC0C36D13Q37279270-7DD54009-EF93-4154-A840-507B9879FD70Q37343893-363BBAEE-FE63-41FE-B970-D7F80141FE2AQ37434580-A1A9F5CA-1DDD-4623-8FE7-F694E3675189
P2860
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oral rivaroxaban versus standa ...... DVT and PE randomized studies.
@en
Oral rivaroxaban versus standa ...... DVT and PE randomized studies.
@nl
type
label
Oral rivaroxaban versus standa ...... DVT and PE randomized studies.
@en
Oral rivaroxaban versus standa ...... DVT and PE randomized studies.
@nl
prefLabel
Oral rivaroxaban versus standa ...... DVT and PE randomized studies.
@en
Oral rivaroxaban versus standa ...... DVT and PE randomized studies.
@nl
P2093
P2860
P356
P1433
P1476
Oral rivaroxaban versus standa ...... DVT and PE randomized studies.
@en
P2093
Alexander T Cohen
Anthonie Wa Lensing
Bonno van Bellen
Bruce L Davidson
EINSTEIN Investigators
Gary E Raskob
Henri Bounameaux
Hervé Decousus
Martin H Prins
Philip S Wells
P2860
P2888
P356
10.1186/1477-9560-11-21
P577
2013-09-20T00:00:00Z
P5875
P6179
1014928695